Mark Levin is the chairman of Voyager’s board of directors and a partner at Third Rock Ventures. He is an industry visionary with 40 years of experience, including more than 30 years launching and building leading biotech companies. Mr. Levin co-founded Third Rock Ventures in 2007 and focuses on the formation, development and business strategy of its portfolio companies, as well as actively identifying and evaluating new investments. Prior to Third Rock, Mr. Levin was co-founder of Mayfield Fund’s life sciences effort, where he was also the founding CEO of Tularik, Cell Genesys/Abgenix, Focal, Stem Cells and Millennium Pharmaceuticals. Mr. Levin served as CEO of Millennium Pharmaceuticals for 12 years. Earlier in his career, he was an engineer and project leader at Eli Lilly and Genentech. He is a member of the National Academy of Engineering and the Friends of Personalized Medicine, and he co-founded the Possible Project in Cambridge, Mass.
Mr. Levin holds a Master of Science degree in chemical and biochemical engineering from Washington University.
Wendy Dixon brings more than 35 years of global biopharmaceutical leadership experience where, as a senior executive, she combined her technical and commercial background to direct the development, launch and growth of over 20 new pharmaceutical products, including many highly successful multibillion dollar global brands across multiple therapeutic areas including oncology, virology, immunology and neurology. Most recently, Dr. Dixon was a senior advisor to The Monitor Group, now Monitor Deloitte, a global consulting firm. From 2001 to 2009, she served as chief marketing officer and president, global marketing for Bristol-Myers Squibb, where she served on the executive committee. From 1996 to 2001, she was senior vice president, marketing at Merck & Co., with prior executive management positions at West Pharmaceuticals, Osteotech and Centocor, and various positions at SmithKline & French Pharmaceuticals (now GlaxoSmithKline) in marketing, regulatory affairs, project management and as a biochemist. Dr. Dixon currently serves on the board of directors of Alkermes, bluebird bio, Eleven Biotherapeutics and Incyte Corporation, and was formerly on the board of Dentsply International, Orexigen Therapeutics, Edimer Pharmaceuticals, Furiex Pharmaceuticals (sold to Actavis plc in 2014) and Ardea Biosciences, Inc. (sold to AstraZeneca plc in 2012).
Dr. Dixon received her Bachelor of Science, Master of Science and Doctor of Philosophy from the University of Cambridge, England, U.K.
Jim Geraghty is an industry leader with 30 years of strategic leadership experience, including more than 20 years developing and commercialization therapies for rare diseases. Mr. Geraghty most recently served as an entrepreneur-in-residence at Third Rock Ventures, focused on creating companies dedicated to improving the lives of patients with rare genetic diseases. Prior to joining Third Rock in 2013, Mr. Geraghty served as senior vice president, north America strategy and business development at Sanofi. Before Sanofi, Mr. Geraghty spent 20 years at Genzyme, as senior vice president and an executive officer, president of Genzyme Europe, and general manager of Genzyme’s cardiovascular business. He also served as chairman and CEO of GTC Biotherapeutics (originally Genzyme Transgenics). He is chairman of Idera Pharmaceuticals and of Juniper Pharmaceuticals, and serves on the board of directors of Fulcrum Therapeutics and of BIO Ventures for Global Health.
A graduate of the Yale Law School, Mr. Geraghty holds a Master of Science from the University of Pennsylvania and a Bachelor of Art from Georgetown University.
Michael Higgins is an experienced biotechnology executive and is currently an entrepreneur-in-residence at Polaris Partners. Previously, he served as chief operating officer and chief financial officer at Ironwood Pharmaceuticals, Inc. from 2003 through 2014. In 2014, Mr. Higgins was named the Boston Business Journal’s CFO of the Year. Mr. Higgins worked at Genzyme Corporation from 1997 through 2003 in a variety of leadership roles, including Vice President of Corporate Finance and Vice President of Business Development. While at Genzyme, he was involved with multiple business units, including cell therapy, gene therapy and orphan diseases. Mr. Higgins also served as chief financial officer of Procept, Inc. from 1992 to 1997. Mr. Higgins began his pharmaceutical career as a sales representative for Schering-Plough Corporation. Mr. Higgins is currently a board member of Genocea Biosciences, Inc. (Nasdaq: GNCA), Pulmatrix, Inc. (Nasdaq: PULM) and Private Equity Access Fund, II.
Mr. Higgins holds a Bachelor of Science from Cornell University and a Master of Business Administration from the Amos Tuck School of Business at Dartmouth College.
Steven Hyman is a renowned leader in neuroscience with more than 20 years of scientific leadership experience. Dr. Hyman has served as director of the Stanley Center for Psychiatric Research at the Broad Institute of Harvard and MIT and as a core faculty member of the Broad Institute since 2012. He has served as a Harvard University Distinguished Service Professor of Stem Cell and Regenerative Biology since 2011. From 2001 to 2011, he served as provost of Harvard University, the university’s chief academic officer. From 1996 to 2001, he served as director of the U.S. National Institute of Mental Health, where he emphasized investment in neuroscience and emerging genetic technologies. Dr. Hyman is the editor of the Annual Review of Neuroscience and president of the Society for Neuroscience (2015). He was elected to the Institute of Medicine, renamed the National Academy of Medicine, in 2000, where he currently serves on the governing Council, the board of Health Science Policy, and chairs the Forum on Neuroscience and Nervous System Disorders, which brings together industry, government, academia, patient groups and foundations. He was founding president of the International Neuroethics Society, a fellow of the American Academy of Arts and Sciences, a fellow of the American Association for the Advancement of Science, a fellow of the American College of Neuropsychopharmacology and a Distinguished Life Fellow of the American Psychiatric Association.
Dr. Hyman received a Bachelor of Art from Yale College, a Master of Art from the University of Cambridge, which he attended as a Mellon fellow, and a Doctor of Medicine from Harvard Medical School.
Perry Karsen has more than 30 years of experience in the biopharmaceutical industry and currently serves as chief executive officer of Celgene Cellular Therapeutics (CCT), the cell therapy research and development division of Celgene Corporation. Mr. Karsen has been the CEO of CCT since May 2013, previously serving as Celgene Corporation’s executive vice president and chief operations officer. Previously, Mr. Karsen was the president and chief executive officer of Pearl Therapeutics, Inc., a privately held biotechnology company subsequently acquired by AstraZeneca plc. He joined Pearl from Celgene, where he was senior vice president and head of worldwide business development, responsible for emerging businesses as president, Asia/Pacific Region, as well as all licensing and strategic collaboration initiatives. Prior to his tenure with Celgene, Mr. Karsen held multiple leadership positions including vice president, business development at Human Genome Sciences, Inc.; vice president, strategic business analysis and development at Bristol-Myers Squibb Co.; senior vice president, marketing and sales at Zimmer, Inc.; director, business development and representative director, Japan at Genentech, Inc.; and various domestic and international roles with Abbott Laboratories. Additionally, he was a general partner at Pequot Ventures responsible for early and late stage investments in biotechnology and medical devices. Mr. Karsen currently serves as a member of the board of directors of the Biotechnology Industry Organization (where he also serves on the executive committee), the Life Sciences Foundation, Inc., Agios Pharmaceuticals, Inc. and Alliqua BioMedical, Inc.
Mr. Karsen received a Master of Management from Northwestern University, Kellogg School of Management, a Master in Teaching of Biology from Duke University and a Bachelor of Science in Biological Sciences from the University of Illinois, Urbana-Champaign.
Steven Paul is our president and chief executive officer, a member of the board of directors and a venture partner at Third Rock Ventures. Dr. Paul brings to Voyager more than 35 years of neuroscience expertise and an extensive track record in CNS drug discovery and development. As venture partner Third Rock, he helps lead the ideation and development of new companies, including Voyager. Before joining Voyager, Dr. Paul was the founding director of the Appel Alzheimer’s Disease Research Institute, where he was the principal investigator of the Institute’s novel adeno-associated virus (AAV) gene therapy program for Alzheimer’s disease, as well as professor of neuroscience, psychiatry and pharmacology at Weill Cornell Medical College. Preceding his appointment at Weill Cornell, Dr. Paul spent 17 years at Eli Lilly, during which time he held several key leadership roles, including president of the Lilly Research Laboratories, and vice president of discovery research and neuroscience research. As president of the Lilly Research Laboratories, he was responsible for the company’s overall R&D strategy, expanding its efforts in oncology and biotechnology and resulting in a pipeline of approximately 70 new molecular entities. Prior to Lilly, Dr. Paul served as scientific director of the National Institute of Mental Health. He has also served as medical director in the Commissioned Corps of the United States Public Health Service. Dr. Paul has authored or co-authored more than 500 papers and book chapters. He is an elected fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Paul currently serves on the board of Sage Therapeutics and Alnylam Pharmaceuticals, and is a chairman of the board for the Foundation for the National Institutes of Health. He previously served on the board of the Sigma Aldrich company, which was acquired by Merck KGaA.
Dr. Paul holds a Bachelor of Art in biology and psychology from Tulane University and a Master of Science and Doctor of Medicine from the Tulane University School of Medicine.
Glenn Pierce serves as entrepreneur-in-residence at Third Rock Ventures, having joined the company in 2016 after more than 30 years of research and development experience working with biotechnology companies. He retired from Biogen in 2014, where he most recently served as chief medical officer leading the hematology, cell and gene therapies division. At Biogen, Dr. Pierce spearheaded the initiation of the Humanitarian Aid Collaboration with the World Federation of Hemophilia (WFH), and My Life Our Future, a population-wide genotyping and genomic biobank initiative. Prior to Biogen, he served in small, large, public and private biotech/biopharma firms, including Bayer, Inspiration, Avigen, Selective Genetics and Amgen in the areas of tissue regeneration and hematology. Dr. Pierce is the co-author of more than 150 scientific papers and received more than15 patents. He served on the medical and scientific advisory council, the board of directors and was president of the board of the National Hemophilia Foundation during a span of two decades. Dr. Pierce also served on the Blood Products Advisory Committee at the FDA and the Committee on Blood Safety and Availability at the U.S. Department of Health and Human Services. He currently serves on the board of directors of the World Federation of Hemophilia and Global Blood Therapeutics.
Dr. Pierce received a Doctor of Medicine and a Doctor of Philosophy in Immunology, both from Case Western Reserve University in Cleveland, and completed his postgraduate training in pathology and hematology research at Washington University in St. Louis.